Natalie Finn, Author at BioTuesdays

Developments

Oramed oral insulin flunks Phase 3 Type 2 diabetes trial

Oramed Pharmaceuticals’ (NASDAQ, TASE ORMP) oral insulin drug candidate, ORMD-0801, did not meet its primary endpoint in a Phase 3 clinical trial in patients with Type 2 diabetes (T2D) at 26 weeks. The multi-center ORA...

January 12, 2023

Developments

liberDi receives FDA clearance for digital home dialysis system

liberDi, a portfolio company of The Trendlines Group (OTCQX:TRNLY), received regulatory clearance from the FDA for its Digital Dialysis Clinic, which allows patients to perform dialysis at home or at the workplace, by...

January 4, 2023

Developments

Kiora completes enrollment in persistent corneal epithelial defects trial

Kiora Pharmaceuticals (NASDAQ:KPRX) completed enrollment in its clinical study evaluating KIO-201 in patients with persistent corneal epithelial defects (PCED), a rare ocular condition characterized by non-healing...

January 3, 2023

Markets

Cantor ups Ardelyx PT to $3 after FDA update

Cantor Fitzgerald raised its price target for Ardelyx (NASDAQ:ARDX) to $3 from $1.60 but maintained a “neutral” rating after a label update from the FDA. The stock closed at $2.51 on Dec. 28. Ardelyx announced that the...

December 29, 2022

Markets

Cantor starts X4 Pharma at OW; PT $3

Cantor Fitzgerald launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with an “overweight” rating and a 12-month price target of $3. The stock closed at 80 cents on Dec. 22. X4 is a clinical-stage biopharmaceutical...

December 22, 2022

Markets

HCW starts Acurx Pharma at buy; PT $14

H.C. Wainwright launched coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $14 price target. The stock closed at $3.83 on Dec. 16. Acurx is a clinical stage biopharmaceutical company focused on...

December 19, 2022

Developments

PharmaJet partner gets fast track for cancer vaccine

PharmaJet partner, Immunomic Therapeutics, received FDA fast track designation for a clinical study of its plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin...

December 13, 2022

Developments

Indaptus initiates Phase 1 trial of Decoy20 in advanced solid tumors

Indaptus Therapeutics (NASDAQ:INDP) initiated INDP-D101, its first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound, Decoy20, in patients with...

December 13, 2022

Developments

IntelGenx, UPEI collaborate on VetaFilm platform in dogs and cats

IntelGenx (TSX:IGX; OTCQB:IGXT) and the University of Prince Edward Island are collaborating on a research project to assess palatability, owner-perceived acceptability, and ease of administration of IntelGenx’s...

December 7, 2022

Developments

Hepion completes enrollment early in Phase 2 ALTITUDE-NASH liver function trial

Hepion Pharmaceuticals (NASDAQ:HEPA) completed enrollment of 60 non-alcoholic steatohepatitis (NASH) stage 3 (F3) subjects in the Phase 2 ALTITUDE-NASH clinical trial. The trial is being conducted in collaboration with...

December 5, 2022

Author - Natalie Finn

Oramed oral insulin flunks Phase 3 Type 2 diabetes trial

liberDi receives FDA clearance for digital home dialysis system

Kiora completes enrollment in persistent corneal epithelial defects trial

Cantor ups Ardelyx PT to $3 after FDA update

Cantor starts X4 Pharma at OW; PT $3

HCW starts Acurx Pharma at buy; PT $14

PharmaJet partner gets fast track for cancer vaccine

Indaptus initiates Phase 1 trial of Decoy20 in advanced solid tumors

IntelGenx, UPEI collaborate on VetaFilm platform in dogs and cats

Hepion completes enrollment early in Phase 2 ALTITUDE-NASH liver function trial

Subscribe